News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
Chris Boerner: The FDA approved our new subcutaneous immunotherapy treatment
Bristol Myers Squibb/LinkedIn
Dec 28, 2024, 15:55

Chris Boerner: The FDA approved our new subcutaneous immunotherapy treatment

Chris Boerner, Board Chair and Chief Executive Officer at Bristol Myers Squibb, posted on LinkedIn:

“Today, the FDA approved our new subcutaneous immunotherapy treatment that offers a patient-centric experience. This is remarkable work that can positively impact the lives of patients with certain types of cancer. Congratulations to my colleagues across Bristol Myers Squibb whose relentless pursuit of bold science contributed to this achievement. Looking forward, we will continue to set the bar even higher because, together, we are defining what’s possible for the future of science and the patients we serve.

Learn more.”

Bristol Myers Squibb cancer Chris Boerner FDA immunotherapy OncoDaily Oncology
Special Coverage
Blog
Jan 31, 2025, 22:43
Yakup Ergün: External-beam radiation versus TACE for HCC
Blog
Jan 31, 2025, 22:43
Mark Lewis: Running, walking, and crawling are all moving forward, just at different speeds
Insight
Jan 31, 2025, 22:43
Issa Mohamad: Survey of Current Practices for Early-Stage Glottic Squamous Cell Carcinoma
Blog
Jan 31, 2025, 22:43
Monika Pansari: Early detection saves lives
Blog
Jan 31, 2025, 22:43
Bhavin Vadodariya: Team work in cancer surgery
Blog
Jan 31, 2025, 22:43
Europe, the time is now: Liver health can’t wait - ELPA
Blog
Jan 31, 2025, 22:43
Wafaa Rashed: Honored to feature Catherine Metayer in this episode of the PAPERI Bright Minds Series
Blog
Jan 31, 2025, 22:43
The first outreach of the year took us to Stem Child Care Academy - Medicaid Cancer Foundation
Blog
Jan 31, 2025, 22:43
Olubukola Ayodele: Thankful to participate in the Cancer Symposium at the University of Leicester
Blog
Jan 31, 2025, 22:42
Transcriptional States and Dynamics of Circulating Tumor-Infiltrating Lymphocytes during Immunotherapy
Insight
Jan 31, 2025, 19:25
Tanja Obradovic: New Phase III trial with an innovative MOA may soon change the standard of care for second-line MSS CRC
Blog
Jan 31, 2025, 18:05
Shining a light on the EU-funded projects - Association of European Cancer Leagues